Does oral inositol hexakisphosphate restore HDAC3 activity and reduce intestinal permeability in inflammatory bowel disease?

We analyzed the available evidence and found that in mouse models of inflammatory bowel disease, oral inositol hexakisphosphate is associated with increased HDAC3 activity, reduced leakage in the intestinal lining, and improved barrier function [1]. This is the only evidence we’ve reviewed so far,...